High expression of HSP110 correlates with MyD88 expression in patients. (A) Representative images of reactive lymph nodes (n = 5) and ABC-DLBCL (n = 35) patients’ lymph node sections stained with HSP110 antibody by IHC. The 2 original magnifications are ×2.8 for A and C (scale bar represents 425 μm) and ×40 for B and D (scale bar represents 30 μm). Representative images of 4 HSP110 intensities are shown beside sections from patients with ABC-DLBCL (original magnification ×20; scale bar represents 60 μm). (B) Schematic representation of HSP110 IHC intensity in the cohort of patients analyzed (n = number of patients with each intensity). (C) Representative image of in cellulo interaction of HSP110 with MyD88 (determined by Duolink technology) in lymph node sections from 2 patients (scale bar represents 40 μm [upper panel] or 20 μm [lower panel]). (D) Immunoblot analysis of HSP110 and MyD88 in biopsies from 13 patients with ABC-DLBCL. HSC70 served as a loading control. (E) HSP110 immunoblot intensity relative to MyD88 from (C).